Canada - English - Health Canada

sanofi-aventis canada inc - metformin hydrochloride - tablet - 1000mg - metformin hydrochloride 1000mg - biguanides

Malta - English - Medicines Authority

alphafarma limited - metformin hydrochloride 500 mg - film-coated tablet

Philippines - English - FDA (Food And Drug Administration)

merck, inc. - metformin hydrochloride - film-coated tablet - 1 g

Philippines - English - FDA (Food And Drug Administration)

n/a; importer: merck, inc.; distributor: n/a - metformin hydrochloride - film-coated tablet - 500 mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck serono ltd - metformin hydrochloride - modified-release tablet - 500mg

Tanzania - English - Tanzania Medicinces & Medical Devices Authority

merck (pty) ltd, south africa - metformin hydrochloride - tablets - 1000mg

Namibia - English - Namibia Medicines Regulatory Council

merck (pty) ltd - metformin hydrochloride - tablets - each film coated tablet contains; metformin hydrochloride 850,0 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - carvedilol, quantity: 25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sucrose; povidone; crospovidone; colloidal anhydrous silica; magnesium stearate - carvedilol watson is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol watson is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii-iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - carvedilol, quantity: 12.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sucrose; povidone; crospovidone; colloidal anhydrous silica; magnesium stearate; iron oxide red; iron oxide yellow - carvedilol watson is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol watson is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii-iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - English - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - carvedilol, quantity: 6.25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sucrose; povidone; crospovidone; colloidal anhydrous silica; magnesium stearate; iron oxide yellow - carvedilol watson is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. carvedilol watson is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii-iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).